(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 7.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.33%.
Bio Techne's revenue in 2026 is $1,228,196,000.On average, 15 Wall Street analysts forecast TECH's revenue for 2027 to be $203,275,400,738, with the lowest TECH revenue forecast at $192,436,140,575, and the highest TECH revenue forecast at $212,857,935,085. On average, 11 Wall Street analysts forecast TECH's revenue for 2028 to be $223,068,832,340, with the lowest TECH revenue forecast at $207,202,668,913, and the highest TECH revenue forecast at $247,260,804,298.
In 2029, TECH is forecast to generate $242,862,263,942 in revenue, with the lowest revenue forecast at $224,482,648,883 and the highest revenue forecast at $260,142,243,912.